Mitsui Chemicals to acquire Ultradent via U.S. holding company
- Mitsui Chemicals America will acquire Ultradent Products for a transaction value of 900 million USD, subject to customary post-closing adjustments.
- The acquisition will be executed via a newly established U.S. Holding Company and is scheduled to complete in September 2026, pending regulatory approvals.
- Ultradent reported consolidated sales of USD 372.1 million and operating income of USD 30.9 million for fiscal year 2025.
- Mitsui plans to transfer the global headquarters of its oral care business to the U.S. and pursue synergies with Kulzer through combined R&D and cross-selling.
Background and purpose
Mitsui Chemicals is prioritising growth in Life & Healthcare, Mobility and ICT, and sees oral care as a core part of its medical-field strategy. Having owned Kulzer since 2013, the group aims to strengthen its Americas presence and expects Ultradent’s design, development and direct-sales capability in teeth whitening and restorative materials to complement Kulzer’s EMEA and restorative strengths.
Method and integration
Mitsui Chemicals America (MCA) will establish a wholly owned U.S. Holding Company to acquire Ultradent’s shares and business assets, accelerate local decision-making, and relocate the oral care global headquarters to that Holding Company. Post-merger integration will combine Mitsui chemical technologies, Ultradent’s clinical expertise and Kulzer’s prosthetic/restorative portfolio to offer broader dental solutions and pursue cross-selling and new product development.
Ultradent overview and financials
Ultradent Products, Inc., headquartered in South Jordan, Utah, was founded in 1978 and develops, manufactures and sells dental products including teeth whitening and restorative materials. For fiscal year 2025 it reported consolidated sales of USD 372.1 million, operating income of USD 30.9 million and net income of USD 24.0 million.
Transaction and schedule
MCA will acquire 1,318 thousand shares (100% of voting rights) from shareholders including founder Dr. Dan Fischer for USD 900 million, with the final price subject to adjustments for working capital and net debt. Board resolution was on May 13, 2026; the acquisition decision and planned execution of definitive agreements were made June 12, 2026. Establishment of the Holding Company and completion of the acquisition are scheduled for September 2026, subject to regulatory approvals and required filings.
Outlook
The impact on Mitsui Chemicals’ consolidated financial results is under review; material items will be disclosed as required.
Source: Mitsui Chemicals
